<DOC>
	<DOCNO>NCT01090024</DOCNO>
	<brief_summary>To investigate effectiveness safety BI 671800 give morning ( AM ) , even ( PM ) twice daily ( b.i.d . ) compare placebo add therapy inhale corticosteroid symptomatic asthma patient .</brief_summary>
	<brief_title>Bi 671800 Asthmatic Patients Inhaled Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed informed consent consistent International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) ( ICHGCP ) 2 . Three month history reversible ( 12 % 200 mL ) asthma accord [ Global Initiative Asthma ( GINA ) ] follow spirometry randomization : forced expiratory volume 1 second ( FEV1 ) 60 % 85 % . 3 . Stable inhaled corticosteroid ( ICS ) dose 3 month prior screen . 4 . Diagnosis asthma prior 40 year . 5 . Asthma Control Questionnaire ( ACQ ) least 1.5 randomization . 6 . Male female , 18 65 year . 7 . Nonsmokers exsmokers ( less 10 pack year history ) negative cotinine screen . 8 . Able perform pulmonary function test ( PFT ) . Exclusion criterion : 1 . Significant disease asthma allergic rhinitis . 2 . Hepatic transaminase total bilirubin great 1.5 upper limit normal ( ULN ) . 3 . Hospitalizations asthma asthma relate intubation within 3 month . 4 . Uncontrolled asthma ICS + another controller . 5 . Respiratory tract infection exacerbation within 4 week . 6 . FEV1 le 40 % , 12 puff short act beta agonist ( SABA ) two consecutive day asthma exacerbation runin period . 7 . Participation another interventional study . 8 . Pregnant nursing woman . 9 . Women child bear potential use appropriate method birth control define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>